Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

10.00 -0.22 (-2.15%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 13, 2025

From Vir Biotechnology, Inc.

Via Business Wire

7 Analysts Have This To Say About Vir Biotechnology ↗

February 28, 2025

Via Benzinga

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

February 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment ↗

January 08, 2025

The company is working to engage the immune system to attack cancer cells.

Via Investor's Business Daily

What's Next: Vir Biotechnology's Earnings Preview ↗

October 30, 2024

Via Benzinga

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

February 12, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why ↗

January 10, 2025

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 08, 2025

Via Benzinga

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why ↗

January 08, 2025

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

Via Benzinga

AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday ↗

January 08, 2025

Via Benzinga

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

January 08, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 18, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

December 12, 2024

From Vir Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 03, 2024

Via Benzinga

AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗

December 03, 2024

Via Benzinga

Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗

December 03, 2024

All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.

Via Investor's Business Daily

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗

December 03, 2024

Via Benzinga

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

November 26, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 25, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

November 18, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

November 18, 2024

From Vir Biotechnology, Inc.

Via Business Wire

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? ↗

November 15, 2024

Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.

Via Benzinga

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

November 15, 2024

From Vir Biotechnology, Inc.

Via Business Wire

What You Missed On Wall Street This Past Friday ↗

November 03, 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

October 31, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

October 17, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024

October 15, 2024

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

October 03, 2024

From Vir Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.